77.01

0.65% 0.50

After Hours: 77.00 -0.01 -0.01%

Gilead Sciences Inc (GILD)

Overview News Price History Option Chain Financials Why GILD Down? Discussions Forecast Stock Split Dividend History

Gilead Sciences Inc stock is traded at $77.01, with a volume of 7.33M. It is up +0.65% in the last 24 hours and up +11.11% over the past month. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Previous Close:

$76.51

Open:

$76.03

24h Volume:

7.33M

Market Cap:

$95.94B

Revenue:

$27.45B

Net Income/Loss:

$484.00M

P/E Ratio:

17.70

EPS:

4.35

Net Cash Flow:

$7.90B

1W Performance:

+6.13%

1M Performance:

+11.11%

6M Performance:

-3.16%

1Y Performance:

-0.23%

1D Range:

$75.74

$78.29

52W Range:

$62.07

$87.86

Gilead Sciences Inc Stock (GILD) Company Profile

Name

Gilead Sciences Inc

Sector

Healthcare (1186)

Industry

Drug Manufacturers - General (17)

Phone

(650) 574-3000

Address

333 LAKESIDE DR, FOSTER CITY, CA

Employee

18,000

Twitter

@GileadSciences

Next Earnings Date

2024-08-08

Latest SEC Filings

GILD's Discussions on Twitter

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-09-23	Initiated	Deutsche Bank	Hold
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy
Sep-06-23	Initiated	HSBC Securities	Reduce
Jul-24-23	Reiterated	Barclays	Equal Weight
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-28-23	Resumed	Piper Sandler	Overweight
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-13-22	Resumed	BofA Securities	Neutral
Dec-09-22	Downgrade	DZ Bank	Buy → Hold
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight
Oct-28-22	Reiterated	BMO Capital Markets	Market Perform
Oct-28-22	Reiterated	Cowen	Outperform
Oct-28-22	Reiterated	JP Morgan	Overweight
Oct-28-22	Reiterated	Jefferies	Buy
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform
Oct-28-22	Upgrade	Truist	Hold → Buy
Oct-28-22	Reiterated	Wells Fargo	Equal Weight
Oct-04-22	Upgrade	JP Morgan	Neutral → Overweight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
May-23-22	Initiated	SVB Leerink	Mkt Perform
Feb-28-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Feb-02-22	Reiterated	BMO Capital Markets	Outperform
Feb-02-22	Reiterated	BofA Securities	Neutral
Feb-02-22	Reiterated	RBC Capital Mkts	Outperform
Feb-02-22	Reiterated	Truist	Hold
Feb-02-22	Reiterated	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Argus	Hold → Buy
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-09-21	Resumed	Wells Fargo	Equal Weight
Dec-06-21	Initiated	Goldman	Neutral
Nov-19-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Nov-19-21	Resumed	Piper Sandler	Neutral
Oct-20-21	Resumed	Cowen	Outperform
Jul-30-21	Reiterated	BMO Capital Markets	Market Perform
Jul-30-21	Reiterated	RBC Capital Mkts	Outperform
Apr-01-21	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-30-21	Upgrade	Redburn	Neutral → Buy
Jan-19-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-21	Upgrade	Guggenheim	Neutral → Buy
Nov-03-20	Resumed	Morgan Stanley	Equal-Weight
Oct-28-20	Initiated	UBS	Neutral
Sep-30-20	Resumed	Jefferies	Buy
Sep-15-20	Upgrade	Maxim Group	Hold → Buy
Jul-31-20	Reiterated	Credit Suisse	Neutral
Jul-31-20	Reiterated	Morgan Stanley	Equal-Weight
Jul-31-20	Reiterated	Piper Sandler	Overweight
Jul-31-20	Reiterated	RBC Capital Mkts	Outperform
Jul-31-20	Reiterated	SunTrust	Hold
Jul-31-20	Reiterated	Wells Fargo	Equal Weight
Jul-20-20	Upgrade	Credit Suisse	Underperform → Neutral
Jun-03-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
May-26-20	Upgrade	SunTrust	Sell → Hold
May-01-20	Downgrade	JP Morgan	Overweight → Neutral
May-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-20	Downgrade	SunTrust	Hold → Sell
Apr-27-20	Downgrade	UBS	Buy → Neutral
Apr-20-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Apr-20-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-17-20	Downgrade	CFRA	Hold → Sell

View All

Gilead Sciences Inc Stock (GILD) Latest News

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by CreativeOne Wealth LLC - MarketBeat

MarketBeat

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

MarketWatch

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 - StockTitan

StockTitan

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

Net Income

Cash Flow

EPS

Gilead Sciences Inc Stock (GILD) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Parsey Merdad	Chief Medical Officer	Jul 01 '24	Sale	68.63	2,000	137,260	96,380
GILEAD SCIENCES, INC.	10% Owner	Apr 02 '24	Buy	0.76	485,250	368,790	7,345,473
Parsey Merdad	Chief Medical Officer	Apr 01 '24	Sale	72.96	2,000	145,920	96,304
Parsey Merdad	Chief Medical Officer	Feb 29 '24	Sale	72.74	8,230	598,624	92,706
Parsey Merdad	Chief Medical Officer	Feb 28 '24	Sale	73.18	2,000	146,360	100,936
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119
GILEAD SCIENCES, INC.	10% Owner	Jan 29 '24	Buy	21.00	15,238,095	319,999,995	30,061,124
Dickinson Andrew D	Chief Financial Officer	Jan 16 '24	Sale	85.78	5,000	428,900	101,534
Mercier Johanna	Chief Commercial Officer	Jan 09 '24	Sale	85.23	8,242	702,466	82,729
Dickinson Andrew D	Chief Financial Officer	Oct 17 '23	Sale	80.00	5,000	400,017	104,003